Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first …

K Kashiwabara, S Fujii, S Tsumura… - Journal of Cancer …, 2021 - Springer
Background The survival benefit of first-line epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) therapy in super-elderly patients with advanced non-small cell lung …
被引用次数：7 相关文章

Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first …

K Kashiwabara, S Fujii, S Tsumura… - Journal of cancer …, 2021 - pubmed.ncbi.nlm.nih.gov
Background The survival benefit of first-line epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) therapy in super-elderly patients with advanced non-small cell lung …

Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first …

K Kashiwabara, S Fujii, S Tsumura… - Journal of Cancer …, 2021 - search.ebscohost.com
Background: The survival benefit of first-line epidermal growth factor receptor-tyrosine
kinase inhibitor (EGFR-TKI) therapy in super-elderly patients with advanced non-small cell …

Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first …

K Kashiwabara, S Fujii, S Tsumura… - Journal of Cancer …, 2020 - europepmc.org
Background The survival benefit of first-line epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) therapy in super-elderly patients with advanced non-small cell lung …

Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first …

K Kosuke, F Shinji, T Shinsuke… - Journal of Cancer …, 2021 - search.proquest.com
Background The survival benefit of first-line epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) therapy in super-elderly patients with advanced non-small cell lung …